margin was higher as the company could be Revenues Gross Profit Selling Admin Net profit 3Q/17 185,920 62,255 17,599 18,053 19,079 3Q/18 249,407 89,092 21,509 18,502 32,736 Change 63,487 26,837 3,910 449
attributable to equity holders of the Company for the period was Baht 22.8 million, decreasing by Baht 67.3 million or 74.7% (Q1/2019: Baht 90.2 million). Profit ratio for the period was 1.3% (Q1/2019: 5.8
Thailand Sustainability Investment 4/ Thailand Sustainability Investment n/a Ranking by Industry Business 4/ Market/Industry/Sector Change Effective Date 02/07/2015 Previous Market/Industry/Sector SET
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
debt to equity conversion scheme where the conversion price will be fixed at THB 0.19613 per share, aggregating not more than THB 4,275,830,130.00 (the “Allocation and Offering of the Newly Issued
afterward. The capital increase from Initial Public Offering would result in the marked decrease in Debt- to-Equity ratio and financial costs going forward. On November 14, 2019, the Company entered into the
., BANGKAE, BANGKAE, BANGKOK, THAILAND. 10160 Tel: 02-455-2888 Fax: 02-455-2763 (“TRANSLATION”) TG 195/2560 November 8, 2017 Subject: Clarification of the Operating Result for the significant change - Update
Equity is, Q3/2017 3 million ba se cost incu fit for the 3 3rd quarter increased pping mall p penses d administra s 68.6% hig inistrative e ar. Most of i ect both sh ent expansio ent of Posit As of 30 S MB
., BANGKAE, BANGKAE, BANGKOK, THAILAND. 10160 Tel: 02-455-2888 Fax: 02-455-2763 (“TRANSLATION”) TG 048/61 February 27, 2018 Subject: Clarification of the Operating Result for the significant change Attention